Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial.

By J. Zajicek, P. Fox, H. Sanders, D. Wright, J. Vickery, A. Nunn, A. Thompson. The Lancet, 2003

786 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

The Endocannabinoid System as an Emerging Target of Pharmacotherapy (2006, background): “…States and supported by the UK Medical Council aimed to explore the effects of cannabis extract (Cannador) or synthetic THC (Marinol) versus placebo on spasticity, pain, tremor, bladder function, and cognitive function [Cannabinoids in Multiple Sclerosis (CAMS) study; Zajicek et al., 2003, 2004].”
Experimental autoimmune encephalomyelitis (EAE) as a model for multiple sclerosis (MS) (2011, background): “…(Bedoui et al., 2003; Luhder et al., 2009) Cannabinoids CB1 and CB2 receptor agonism Improvement (Arevalo-Martin et al., 2003; Pryce et al., 2003; Zajicek et al., 2003; Ni et al., 2004; Maresz et al., 2005; Rog et al., 2005; Freeman et al., 2006; Wissel et al., 2006; Centonze et al., 2007;…”
Cannabinoid-based drugs as anti-inflammatory therapeutics (2005, methodology): “, has been analysed in clinical trials and has been shown to have efficacy in reducing spasms and stiffnes”
A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. (2006, background): “Although labelled as ‘standardised’, clear variation in cannabinoid content has been reported in available studies with THC:CBD ratios noted as 2.5:0.9 [45], unspecified [43], or 2.5:1.25 = 2:1[46,50], or just 2.5 mg of THC with no mention of CBD [47].”